Moncef Slaoui

Dr. Moncef Slaoui is an Independent Director at Vaxcyte, Inc., a Chairman at Arcturus Therapeutics Holdings, Inc., a Venture Partner at Medicxi Ventures (Jersey) Ltd. and a Chairman at Altesa BioSciences, Inc. He is on the Board of Directors at Vaxcyte, Inc., Biotechnology Innovation Organization, Monopteros Therapeutics, Inc. and Zephyr AI, Inc. Dr. Slaoui was previously employed as an Independent Director by Lonza Group AG, an Independent Non-Executive Director by Moderna, Inc., a Chairman by Galvani Bioelectronics Ltd., a Director, Chairman-Research & Development by Genelabs Technologies, Inc., an Executive Director & Chairman-Global Vaccines by GlaxoSmithKline Plc, a Director & Strategic Advisor by Longwood Fund Management LLC, a Professor by Université de Mons, and an Immunology Professor by University of Mons Hainaut.
He also served on the board at Intellia Therapeutics, Inc., PhRMA Foundation, Agency for Science, Technology & Research, Artizan Biosciences, Inc., International AIDS Vaccine Initiative, Inc., ModernaTX, Inc. and Pharmaceutical Research & Manufacturers of America.
He received his graduate degree from Tufts University, a graduate degree from Harvard Medical School, an MBA from the International Institute for Management Development and a doctorate degree from Université Libre de Bruxelles.